title: Biomarkers: the future.
abstract: The future application of biomarkers in critical illness will be to select and guide therapy. Specific biomarkers could identify a pathophysiologic perturbation or noxious mediator to counteract or the need to replete a deficient protective protein. Functional genomics could identify patients at risk for illness or at risk for a poor outcome in critical illness. Genetic expression studies could help differentiate patients with sepsis from those with noninfectious inflammation and could also help to monitor illnesses over time. Expressional and functional proteomics could lead to the identification of new biomarkers and organ-specific therapies.
authors: Warren Alpert School of Medicine, Brown University, 171 Meeting Street, Providence, RI 02912, USA. slarosa@lifespan.org
authors: Steven P
authors: SP
authors: LaRosa
authors: Steven M
authors: SM
authors: Opal
mesh_terms: D000510:Alpha-Globulins / Q000378:metabolism; D042683:Angiopoietin-1 / Q000097:blood; D042702:Angiopoietin-2 / Q000097:blood; D015415:Biomarkers; D003422:Critical Care; D004731:Endotoxins / Q000097:blood*; D018260:Gelsolin / Q000097:blood; D015870:Gene Expression; D006684:HLA-DR Antigens; D006801:Humans; D020641:Polymorphism, Single Nucleotide; D040901:Proteomics; D018805:Sepsis / Q000235:genetics* / Q000378:metabolism*
chemical_list: D000510:Alpha-Globulins; D042683:Angiopoietin-1; D042702:Angiopoietin-2; D015415:Biomarkers; D004731:Endotoxins; D018260:Gelsolin; D006684:HLA-DR Antigens; C011877:inter-alpha-inhibitor